Lynch syndrome — a hereditary mismatch-repair-deficient predisposition whose shared frameshift neoantigens enable preventive ('interceptive') vaccines.
Radboud University Medical Center is initiating a Phase I/II trial for preventive dendritic cell vaccination in Lynch Syndrome carriers. This represents a shift toward prophylactic neoantigen strategies, targeting individuals with germline MMR mutations before tumor development to assess safety and immunogenicity.
Molecular characterization of precancerous lesions in Lynch syndrome carriers confirms that Nous-209 target mutations occur early in adenoma progression, supporting the vaccine's preventive potential. The study found that Nous-209 mutation counts correlate strongly with microsatellite instability status, with dMMR/MSI-H lesions harboring the highest burden, validating the target population for this NCI-sponsored Phase Ib/II trial.
The NCI is running a Phase Ib/II trial of the Nous-209 vaccine in Lynch syndrome patients to evaluate safety, immune response, and potential effects on polyp or tumor development. The vaccine consists of man-made copies of neoantigens generated by mismatch repair errors, targeting the high-risk colorectal cancer population associated with inherited genetic variants.
Nature publishes results from a Phase 1b/2 trial of the Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers. The publication provides clinical data on the vaccine's ability to intercept cancer development in genetically predisposed individuals, a key differentiator in the neoantigen landscape.
Oncodaily highlights a new paper on Nous-209, a neoantigen vaccine designed for cancer interception in Lynch syndrome carriers. This focus on prevention in high-risk genetic populations signals a strategic expansion of neoantigen vaccines beyond therapeutic treatment to early-stage disease modification.